



Post Authorisation Assessments

Meloxaid 1.5 mg/ml Oral Suspension for Dogs Vm 39787/3000

03 March 2025	Submission of a new Ph. Eur. CEP from an already approved manufacturer for an active substance.
18 May 2024	Updated CEP submitted for the manufacture of an active substance.
27 March 2024	Changes to the labelling or the package leaflet which shall not be connected with the SPC: – other changes.
26 January 2024	Approval of mock ups.
26 September 2023	Change in distributor details from EU Pharmaceuticals, 37 Geraldine Road, SW18 2 NR, London to CVS (UK) Limited, CVS House, Owen Road, DISS, Norfolk, IP22 4ER.
14 August 2023	Change in the invented name of the veterinary medicinal product from Rheumoxidyl 1.5 mg/ml oral suspension for dogs to Meloxaid 1.5 mg/ml oral suspension for dogs.
15 June 2023	Change in dimensions of the container or closure for the finished product.
25 May 2023	Minor change in the manufacturing process.
10 March 2023	Change in the specification of the finished product to describe more accurately the appearance of the product.